Since the beginning of 2024, the brain-computer interface (BCI) concept has gained significant momentum in China’s A-share market, with 10 related stocks achieving consecutive daily trading limits (known as ‘lianban’), drawing widespread investor attention. This rally is driven by a combination of supportive government policies, technological breakthroughs, and accelerated investment from industrial capital. Recently, national policy documents have repeatedly emphasized accelerating the development of cutting-edge technologies in artificial intelligence and human-computer interaction, providing a favorable regulatory environment for the BCI sector. Additionally, global tech leaders like Neuralink have reported progress in clinical trials, further fueling investor enthusiasm for domestic BCI-related firms. Companies such as Innovation Medical, Sinocare, and Fudan Fuhua have seen strong market interest due to their involvement in EEG signal acquisition, neural decoding algorithms, or BCI hardware development. However, industry experts caution that most BCI companies are still in the R&D or early commercialization phase, with limited earnings to justify current valuations. Investors are advised to remain cautious about short-term speculation and carefully distinguish between hype and long-term fundamentals.
2024年开年以来，A股市场脑机接口概念持续升温，已有10只相关概念股实现连续涨停（连板），引发市场高度关注。这一轮上涨主要受到政策支持、技术突破及产业资本加速布局等多重因素推动。近期，国家层面多次提及加快人工智能与人机交互前沿技术发展，为脑机接口领域注入政策红利。同时，全球科技巨头如Neuralink等在临床试验方面取得阶段性进展，进一步激发了投资者对国内相关企业的想象空间。从市场表现看，包括创新医疗、三诺生物、复旦复华等在内的多家公司因涉及脑电信号采集、神经解码算法或脑机硬件研发而被资金热捧。不过，业内人士也提醒，当前多数脑机接口企业仍处于技术研发或早期商业化阶段，实际业绩支撑有限，投资者需警惕短期炒作风险，理性看待概念热度与长期价值之间的差距。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/10966.html